immunology-congress-2018-posters-abstracts

9 / 21

Page 39
Notes:
allied
academies
Journal of Timely Topics in Clinical Immunology | Volume 2
July 26-28, 2018 | Moscow, Russia Immunology
11th Annual Congress on
Antiphospholipid antibodies: Clinical and diagnostic problem as an intriguing notion on Immunology
Ljudmila Stojanovich
University Medical Center, Serbia
Antiphospholipid syndrome (APS) is defined by clinical
manifestations that include thrombosis and/or fetal loss
or pregnancy morbidity in patients with antiphospholipid
antibodies (APL). Diagnostic Problem: Antiphospholipid
antibodies are among the most common causes of acquired
thrombophilia, but unlike most of the genetic thrombophilias
are associated with both venous and arterial thrombosis.
Antiphospholipid antibodies are directed primarily toward
phospholipid binding proteins rather than phospholipid per se,
with the most common antigenic target being β2-glycoprotein
1 (β2GPI) although antibodies against other targets such as
prothrombin are well described. Laboratory diagnosis of aPL
depends upon the detection of a lupus anticoagulant (LA),
which prolongs phospholipid-dependent anticoagulation tests,
and/or anticardiolipin and anti-β2-glycoprotein 1 antibodies.
Indefinite anticoagulation remains the mainstay of therapy for
thrombotic APS, although new strategies that may improve
outcomes are emerging. Clinical Problem: While the clinical
presentation of APS can be quite diverse because the disease
can affect virtually any organ system, patients typically present
with symptoms relating to joint, skin or mucosal inflammation,
or with a varying degree of haematological abnormality or
constitutional features. However, the lack of a gold standard
test to confirmdiagnosis often results in delays or misdiagnosis.
e